European Pharmaceutical Review

DECEMBER 12, 2022

Utrogestan 100mg, a product by Besins Healthcare UK, is a body-identical hormone, which means it has the same molecular structure as the hormone produced by the body. Del Cohen, Managing Director at Besins Healthcare UK, stated: “Utrogestan offers women an increased choice in approved medicines for HRT.

95

95

European Pharmaceutical Review

SEPTEMBER 18, 2023

The Cell and Gene Therapy Catapult (CGT Catapult) , supported by Scotland’s national economic development agency, Scottish Enterprise, has launched a new cooperative network to foster collaboration and increase knowledge sharing across the Advanced Therapy Medicinal Products (ATMP) industry in Scotland.

Vaccines 93

Vaccines 93

European Pharmaceutical Review

JUNE 7, 2023

As its first facility in Scotland, the Cell and Gene Therapy Catapult (CGT Catapult) has opened new laboratories located in the Edinburgh BioQuarter, at the University of Edinburgh’s Institute of Regeneration and Repair. Supporting the UK’s cell and gene therapy industry Since 2012, there has been over £5.5

86

86

pharmaphorum

OCTOBER 14, 2021

UK-based Big Health has passed a digital health milestone after Scotland became the first country to make anxiety and insomnia digital therapeutics available on a national basis. We are proud to expand our service in Scotland to support the Scottish Government’s world-leading mental health strategy.”.

People Management 96

People Management 96

pharmaphorum

JULY 26, 2022

Newly diagnosed cancer patients across the UK will get free access to digital mental health therapies, thanks to a new partnership between Macmillan Cancer Support and Big Health. All Scottish adults already have access to Sleepio and Daylight, under a partnership with NHS Scotland, it added. Photo by Yuris Alhumaydy on Unsplash.

134

134

Pharmafile

FEBRUARY 3, 2023

Published date: 03/02/2023 Summary: Phlo, UK digital pharmacy leaders, have closed a £10m Series A round. Glasgow, Scotland] Phlo, UK digital pharmacy leaders, have closed a £10m Series A round led by family office Thairm Bio. read more

73

73

Pharmafile

APRIL 12, 2023

Published date: 12/04/2023 Summary: • Scottish Medicines Consortium decision based on the DESTINY-Breast03 trial results which demonstrated a significant improvement in progression-free survival (PFS) and overall survival (OS) with trastuzumab deruxtecan versus trastuzumab emtansine.

52

52

European Pharmaceutical Review

MARCH 14, 2023

The Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Hepcludex ® (bulevirtide) for chronic hepatitis delta virus (HDV) infection. All eligible patients will now have the option of the only treatment conditionally approved for HDV infection via NHS Scotland.

79

79

pharmaphorum

JULY 27, 2022

Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Despite the UK’s potential as an international life sciences leader, it lags many competitors in a number of key metrics, including access to new medicines and global share of clinical trial recruitment. Access to medicines.

Documentation 98

Documentation FDA 98

Hospital Pharmacy Europe

DECEMBER 19, 2023

This includes ‘up to £18m‘ from the UK ‘to support partner countries to assess vulnerability, identify priority actions and support planning… to better cope with the impacts of climate change‘. It also considered the various innovative ways that these emissions can be reduced if the NHS in Scotland is to meet its ambition to achieve net zero.

Hospitals 52

Hospitals 52

pharmaphorum

NOVEMBER 11, 2021

A firm order for VLA2001 throws a lifeline to Valneva, which was hit hard when the UK government backed out of a supply deal for up to 190 million doses of the shot – valued at €1.4 Shares in Valneva strengthened by a quarter after the EU deal was announced, recovering ground lost after the UK terminated its contract.

Vaccines 102

Vaccines 102

pharmaphorum

DECEMBER 22, 2020

The UK government is funding a network of three centres that will use digital technology to train the next generation of scientists specialising in advanced therapies. The post UK funds digital training centre for advanced therapy skills appeared first on. The ATSTN programme, which launched on 2nd December , is backed by £4.7m

Vaccines 72

Vaccines 72

pharmaphorum

JANUARY 18, 2022

Scotland has approved AstraZeneca’s Tagrisso (osimertinib) as a monotherapy for the for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. NSCLC is the most common form of the disease.

59

59

pharmaphorum

OCTOBER 12, 2021

Patients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb’s immunotherapy Opdivo with Ipsen’s targeted drug Cabometyx, ahead of the rest of the UK and most other countries in the world. months with sunitinib.

52

52

pharmaphorum

FEBRUARY 25, 2021

The rare disease community has a golden opportunity to transform the way care is delivered across all four UK nations – that’s according to speakers at a parliamentary reception held to mark 2021’s Rare Disease Day. The framework is a UK-wide commitment from the four nations to make progress on these priorities.

Documentation 96

Documentation Labelling 96

European Pharmaceutical Review

FEBRUARY 29, 2024

“This is tremendous news and means that for the very first time people who have AL amyloidosis will be able to gain access to this treatment combination,” stated Dr Sophie Castell, Chief Executive, Myeloma UK. She emphasised this recommendation is significant because DVCd “has been available in Scotland and Northern Ireland since 2022”.

Documentation 97

Documentation Pharmaceutical Companies Pharmaceutical Companies 97

pharmaphorum

MAY 24, 2022

Industrial action at several GlaxoSmithKline manufacturing plants in the UK has been called off, after an improved pay deal was accepted by the Unite union. The six plants affected by the ballot were Montrose and Irvine in Scotland, Ware in Hertfordshire, Worthing in West Sussex, Barnard Castle in Durham, and Ulverston in Cumbria.

98

98

pharmaphorum

JANUARY 19, 2021

Rozlytrek (entrectinib) can now be used by the NHS in Scotland as a treatment option for ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors. NICE has previously estimated that roughly 412 patients across the UK are have NSCLC eligible for treatment with Rozlytrek.

Chemotherapy 94

Chemotherapy Immunization 94

pharmaphorum

APRIL 13, 2021

A disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland gave a green light to use of PTC Therapeutics’ Translarna for the first time. . — Duchenne UK (@DuchenneUK) April 12, 2021. Dupixent recommended after NICE rejection.

52

52

Pharma Times

NOVEMBER 29, 2021

An additional six cases of the Omicron variant have now been detected in Scotland, bringing the UK total so far to nine.

49

49

pharmaphorum

NOVEMBER 8, 2022

In the UK alone, the disease affects around 8,000 people each year. Previously, there was no immunotherapy treatment option available for people with early stage or locally advanced TNBC, creating an unmet need for these patients,” said David Long, head of oncology at MSD UK. After a median follow-up of 39.1

Chemotherapy 108

Chemotherapy 108

pharmaphorum

NOVEMBER 29, 2021

” It says the interested parties include UK biotech Oxford BioMedica, Swiss chemicals group Lonza, and Japan’s Fujifilm, which has subsidiaries that provide contract development and manufacturing services to the pharma industry. The post Report suggests UK’s national vaccine facility is on the block appeared first on.

Vaccines 100

Vaccines 100

pharmaphorum

JULY 22, 2022

A just-published report on the UK’s life sciences sector “ought to ring alarm bells across government,” according to the Association of the British Pharmaceutical Industry (SBPI). In the UK, the set-up and recruitment of patients takes longer than the approval process, says the report. Draft finance bill.

Documentation 52

Documentation 52

pharmaphorum

SEPTEMBER 15, 2021

The European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to supply COVID-19 vaccines that was terminated by the UK government this week. That would throw a lifeline to Valneva, which was rocked by the UK’s decision to withdraw from the €1.4

Vaccines 116

Vaccines 116

Hospital Pharmacy Europe

APRIL 11, 2024

Back for a second year, the Clinical Excellence events series brings together renowned experts from recognised Centres of Excellence and other UK and European hospitals to share their experiences of clinical innovations, examples of best practice and how they are improving patient care.

Hospitals 52

Hospitals Patient Care 52

pharmaphorum

OCTOBER 14, 2020

A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) backed NHS use of two drugs previously turned down by NICE in England. The post Scotland backs two myeloma drugs turned down by NICE in England appeared first on. Image by Neil Cumins from Pixabay.

52

52

pharmaphorum

FEBRUARY 1, 2021

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses. In a separate development, the UK government has exercised an option for 40 million doses of another potential coronavirus vaccine from Valneva.

Vaccines 114

Vaccines 114

pharmaphorum

OCTOBER 11, 2022

Wellcome has provided funding in the UK to help answer that question. One exception to that is Big Health’s digital cognitive behavioural therapy (CBT) course Sleepio for insomnia, which was broadly adopted by NHS Scotland last year, and recently endorsed by NICE for use by NHS England. The healthcare charity is providing £1.8

107

107

pharmaphorum

OCTOBER 11, 2022

Scotland has become the first country in the UK to back NHS funding for the use of Merck & Co/MSD’s Keytruda in combination with Eisai’s Lenvima as a treatment for advanced or recurrent endometrial cancer. The post Scotland backs three new uses for MSD’s Keytruda appeared first on.

Chemotherapy 52

Chemotherapy Documentation 52

IDStewardship

MAY 21, 2023

Jude/PIDS Pediatric Infectious Diseases Research Conference March [link] ACVR NFID Annual Conference on Vaccinology Research, takes place online March [link] WCID Winter Course in Infectious Disease, takes place in USA and virtual February [link] CLSI Meetings Clinical Laboratory Standards Institute, current listings take place in USA Various [link] (..)

Chemotherapy 130

Chemotherapy 130

European Pharmaceutical Review

NOVEMBER 30, 2022

The UK-based Centre for Process Innovation (CPI) has opened its £88 million Medicines Manufacturing Innovation Centre in Glasgow, Scotland, to help accelerate medicine development by focusing on small molecule and fine chemical manufacturing and sustainable manufacturing. The facility is part of CPI’s series of ?‘Grand

80

80

Hospital Pharmacy Europe

JANUARY 18, 2023

Around 1000 patients could benefit from this at-home treatment each year. Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK , said: “ IRD is a game-changer and we’re absolutely delighted with NICE’s decision.

Hospitals 98

Hospitals 98

pharmaphorum

NOVEMBER 16, 2021

Epilepsy affects more than 600,000 people in the UK and for some, seizures can be life-threatening. It is estimated that around 1,000 people die in the UK every year because of the condition. An opinion from the Scottish Medicine Consortium (SMC) on the use of the drug by NHS Scotland is expected to be published early in 2022.

Documentation 96

Documentation 96

pharmaphorum

APRIL 12, 2021

The app used in Scotland isn’t affected because it has developed a separate app for venue check-ins, rather than building that functionality into the Protect Scotland contact-tracing app, according to the BBC.

138

138

Hospital Pharmacy Europe

JANUARY 24, 2024

They were developed with input from ‘a broad range of stakeholders from across the pharmacy sector in England, Scotland, and Wales’, the GPhC said, and follow the ratification of The Pharmacy (Preparation and Dispensing Errors – Hospital and Other Pharmacy Services) Order.

Hospitals 105

Hospitals 105

pharmaphorum

APRIL 1, 2022

The move – which comes after an agreement by UCB to reduce the price of the drug – makes Evenity (romosozumab) the first novel therapy for the bone-wasting condition to be available to the NHS across the UK in more than a decade. ” The post NICE ends UK access disparity to osteoporosis drug Evenity appeared first on.

Documentation 59

Documentation 59

pharmaphorum

DECEMBER 13, 2021

The UK government has said it will step up its COVID-19 booster vaccination dramatically, with everyone in England aged over 18 offered a third dose before the end of the month. So far, there have been 10 confirmed hospitalisations in the UK involving Omicron, but no deaths attributed to the new variant, said Javid.

Vaccines 52

Vaccines 52